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ABSTRACT
Alzheimer’s Disease Association With Chlamydia pneumoniae
Andrew Short
MS in Biomedical Sciences, August 2011
Department of Pathology, Microbiology, Immunology and Forensic Medicine
Philadelphia College of Osteopathic Medicine, Philadelphia, PA
C. Scott Little, Ph.D. Thesis Advisor
Abstract
Exogenous bacteria, such as Chlamydia pneumoniae, may be a cause of
inflammation that contributes to the progression of Alzheimer’s disease (AD).
Inflammation has been previously established as a contributor to AD progression. Balin
et al. first reported C. pneumoniae in the brains of post-mortem late onset AD patients.
PCR analysis showed that 17/19 AD patients were positive for the organism in areas of
the brain with typical AD-related neuropathology while 18/19 control patients were PCRnegative. Gérard et al. determined, using real-time PCR, that C. pneumoniae-infected
cells colocalize with both neuritic senile plaques and neurofibrillary tangles, the defining
pathologies of AD.
Several research groups have independently replicated detection of C.
pneumoniae in AD brains, whereas a number of research groups did not detect the
organism. The variability in detection results demonstrates the need for a standardized
technique to produce accurate and dependable results amongst research groups.
The goal of this work is to optimize a sensitive and specific technique to detect C.
pneumoniae in experimentally infected olfactory bulb (OB) and frontal cortex (FC) tissue
from mice after 3 days and 14 days following direct intracranial infection with 1X103
infectious forming units (IFU) using a PrimerDesign™ genesig 16S ribosomal RNA
sequence RT-PCR advanced Chlamydia detection kit.
Chlamydia pneumoniae was successfully detected in 2X106 monocytic cell line
THP-1 infected with C. pneumoniae for 48 hours at a multiplicity of infection (MOI) of
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0.75. The lowest amount detected was at a dilution of 1:500,000 (0.04ng total DNA),
which was approximately 3 infected cells of the 2X106 total. Experimental samples were
considered positive if a sample amplified a Chlamydia-specific 16S RNA sequence in at
least 1 reaction, crossing the threshold (CT) at less than 40 cycles, which was based on a
dilution series of positive control infected THP-1 cells.
C. pneumoniae was also detected in CNS tissue following inoculation at both day
3 and day 14 samples using RT-PCR. Total DNA content of 400 and 800ng/reaction
were not sufficient amounts to accurately and consistently detect C. pneumoniae.
However, when using a total DNA content of 1500ng/reaction, C. pneumoniae was
detectable when present in both day 3 and day 14 samples.
Trends in the data show that by increasing the total DNA content, samples that
were previously inconsistently positive, or even negative, now showed presence of
Chlamydia-specific sequence amplification. In 24 samples tested at 400ng/reaction, 9
were detected and only 3 of those 9 were considered positive. Conversely, at
1500ng/reaction, 34 of 44 samples amplified Chlamydia-specific 16S RNA, 9 of which
were considered positive.
A total of 16 experimental tissue samples were analyzed, 8 at day 3 and 8 at day
14-post infection. Samples 005 and 053 were injected with vehicle only and served as
negative controls. Day 3 samples considered positive were FC-006, 007, and 008 as well
as OB-007 and 008. Positive day 14 samples were FC-056 and OB-055 and 056.
Assigning undetected samples a CT value of 50, the last cycle for the reaction, the
average CT value at 400ng/reaction is 47.4 and at 800ng/reaction it is 47.6. Raising the
content to 1500ng/reaction gives a mean CT value of 44.4. Furthermore, 30 of the 48
samples were undetected at both 400 and 800ng/reaction while at 1500ng/reaction only
10 of the 44 reactions were undetected.
These results suggest that a PrimerDesign™ genesig 16s ribosomal RNA
sequence RT-PCR advanced Chlamydia detection kit is suitable for detection of C.
pneumoniae in experimental samples. We were also able to determine that
1500ng/reaction is a suitable minimum for total DNA content as we were able to produce
consistent results using 1500ng/reaction. One future consideration would be to increase
the total DNA content to 2000-2500ng/reaction. Doing so may result in increased
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sensitivity and lower, more consistent, CT values that parallel the infeceted THP-1
positive control.
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INTRODUCTION
I. Alzheimer’s Disease
Alzheimer’s disease (AD) is the most common form of dementia and accounts for
50 to 80 percent of dementia cases. Alzheimer’s disease is a severe mental disorder that
currently affects as many as 5.3 million Americans [1]. Of those affected, 7% are aged
65-74, 53% are 75-84, and 40% are over 84 years of age. At the current rate of diagnosis,
an estimated 13 million Americans will have the disease by 2050 [2]. Additionally, AD
prevalence varies within these age groups. The prevalence increases from 4% for the 6575 year age group to 19% in the 85-89 year age group. Incidence also increases from
7/1000 in the 65-69 year age group to 118/1000 in the 85-89 year age group [3].
It is well understood that AD appears in two distinct, yet related, forms. The first
form, familial AD, progresses rapidly and causes patients to display symptoms prior to 60
years of age [4]. Causes of this form of AD have been linked to gene mutations on
chromosomes 1, 14, and 21. Mutations on chromosome 1 cause production of abnormal
presenilin-2 (ps-2) and mutations on chromosome 14 cause production of abnormal
presenilin-1 (ps-1). Mutations to chromosome 21 lead to an abnormal formation of
amyloid precursor protein (app). Each of these mutations causes the amount of betaamyloid protein produced to increase; beta-amyloid is a major component of AD plaques
[5].
The second form, and the focus of this research, is sporadic, or late-onset, AD.
Sporadic AD appears after the age of 60 years old, with risk of development increasing
with age. The incidence rate is 53 new cases per 1,000 people between the ages of 65
and 74, while among people between 75 and 84 years old have 70 new cases per 1,000
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people. The most AD prone age group is people over the age of 85, as they have 231
new cases per 1,000 people [6]. Although age increases the risk of AD development,
genetic factors have been identified as risk factors as well.
The plasma lipid transport protein, apolipoprotein E (apoE), gene is found on
chromosome 19. The ε2, ε3, and ε4 alleles of apoE are the most significant genetic
factors in sporadic AD development [5]. These isoforms are created due to dissimilarity
in two amino acids at positions 112 and 158. The resulting structural differences cause a
conformational change and influence the protein’s ability to stably bind to lipoprotein
particles. In addition, other physiological apoE properties affected by the presence of
either arginine or cysteine at positions 112 and 158 include anti-oxidant, anti-apoptotic,
immunomodulatory, and atheroprotective capacity [7]. These properties create
conditions that cause isoform-specific effects on development of several chronic diseases,
such as ApoE ε4-associated risk pertaining to atherosclerosis, stroke, and AD [7]. ε3 is
the most common allele with ε3/3 being the most common genotype [8,9]. Though ε3 is
the most common allele, it is not associated with an increase or decrease in risk of AD
development [5]. A recent study showed that 53.1 percent of AD patients selected
possessed the ε3 allele. More specifically, 7.4 percent of the patients had the ε2/ε3
genotype while 28.2 and 42.3 percent of the patients had the ε3/3 and ε3/4 genotypes,
respectively. The ε3 allele is present about 45 percent of the time in AD patients between
the ages of 60-79 and about 65 percent of the time in patients from 80-89, thus displaying
its relative neutrality in association with sporadic AD. The ε2 allele is by far the most
underrepresented of the three alleles and has been shown to have no significant effect on
age of onset [9]. However, some research shows that the ε2 allele may be somewhat
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protective against induction of sporadic AD, as seen by the lower incidence rates when
combined with the neutral ε3 allele [10].
The ε4 allele is the only well confirmed risk factor linked to sporadic AD. This
allele has been associated with poor clearance and recycling of lipoprotein particles
carrying cholesterol and Aβ peptides, a common pathology of AD [7]. One copy of the
ε4 allele increases the risk of AD occurrence by about 3 times while two copies increases
the risk by about 12 times [10]. A 2008 study showed that people without the ε4 allele
had a mean age of onset of 78.4 years of age while people with the ε4 allele had an age of
onset of 75.3 years of age. Furthermore, the age of onset was reduced to 72.9 years of
age when patients had two ε4 alleles [9]. It should also be noted that the ε4 allele had a
marked decrease in frequency with patients under the age of 65, the approximate
distinction between sporadic and familial AD [11]. Overall, the ε4 allele is shown to
significantly increase one’s risk of developing AD at an earlier age.
Though familial and sporadic AD have different inducing factors, they share
hallmark neuropathologies of extracellular neuritic senile plaques (NSPs) and
intraneuronal neurofibrillary tangles (NFTs). The NSPs are primarily made up of betaamyloid (Aβ) protein whereas NFTs are primarily made up of modified tau protein [5].
Amyloid-β peptides are natural products of metabolism with monomers of Aβ40
being more prevalent that the aggregating Aβ42 variety [12]. Alzheimer’s disease is
initiated when an imbalance in production and clearance occurs, causing Aβ to
accumulate. Amyloid-β peptides spontaneously self-aggregate into physical forms
including soluble oligomers and insoluble fibrils. Soluble oligomers combine to form
intermediate assemblies, both of which are the most neurotoxic forms of Aβ [12].
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Severity of cognitive loss associated with AD is related to the level of oligomers in the
brain rather than the total amount of Aβ present. Insoluble fibrils arrange themselves into
β-pleated sheets to form insoluble fibers found in advanced amyloid plaques [12].
Neurofibrillary tangles are filamentous inclusions in pyramidal neurons that
consist primarily of hyperphosphorylated tau protein aggregations [12]. Tau is normally
an abundant soluble protein found in axons and promotes assembly and stability of
microtubules and vesicle transport. When hyperphosphorylated, tau becomes insoluble
and lacks affinity for microtubules, self-associating into paired helical filamentous
structures. Like Aβ oligomers, intermediate aggregates of modified tau are cytotoxic and
impair cognition. Insoluble helical filaments may be inert as they sequester toxic
intermediate tau, possibly having a protective mechanism [12]. Because of these tau
protein aggregations, proper neuronal function cannot occur and cognitive deficit ensues.
Amyloid-β accumulation precedes tau aggregation and has been shown to
promote this process. Additionally, Aβ-induced degeneration of neurons and cognition in
mice with AD-like illness requires the presence of endogenous tau [12]. Overall,
oxidative stress, impaired folding function at the endoplasmic reticulum, and deficient
proteasome-mediated and autophagic-mediated clearance of damaged proteins
accelerates the accumulation of amyloid and tau proteins in AD [12].
A. Inflammation and Alzheimer’s Disease
Inflammation has also been investigated as a contributor to AD progression as
senile plaques and Aβ deposits are surrounded by activated immune cells capable of
releasing proinflammatory molecules including chemokines and cytokines [13]. This
inflammation occurs because of an endogenously mediated, localized reaction that is
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similar to that mounted in the periphery when localized tissue is invaded by foreign
material.
Specifically, microglia and astrocytes are capable of producing all proinflammatory elements in the AD brain. Astrocytes are immunologically activated by a
variety of stressors and respond to and produce inflammatory mediators. Upon
activation, reactive astrocytes cause upregulation in glial fibrillary acidic protein
expression, astrocyte swelling, hypertrophy, hyperplasia, and gliosis. Advanced stages of
AD show a nearly four-fold increase in astrocyte amount [14]. Recent evidence indicates
that astrocyte accumulation creates barriers and reduces efficiency of deposited Aβ
clearance [14].
Microglial cells have macrophage-like characteristics and possess phagocytic
capabilities, and upon activation express MHC II and several other macrophage-like proinflammatory molecules [14]. Microglia of the AD brain have altered morphology and
increased expression of MHC II, cytokines, chemokines, and other neurotoxins, all of
which can cause local or widespread central nervous system injury [14]. Both microglia
and astrocytes are co-localized with neuritic plaques and Aβ deposits in the AD brain.
Inflammation has also been shown to be co-localized in regions of the brain that have
high levels of AD pathology and absent in regions that do not display neuropathology
[15].
Neurons and microvessels further exacerbate the inflammatory response in the
AD brain. Neurons are capable of producing inflammatory mediators such as
complement, cyclooxygenase, pro-inflammatory cytokines, IL-6, gp130, and
mononuclear phagocyte colony-stimulating factor (M-CSF) [14]. Microvessels of the
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AD brain have demonstrated release of significantly higher levels of IL-1β, IL-6, and
TNF-α under basal, unstimulated conditions relative to non-AD microvessels. Elevated
levels of these molecules in the AD brain play a role in the pathogenesis of neuronal
injury [16]. Production of inflammatory mediators causes neuronal injury to worsen and
can lead to loss of cognitive function as seen in AD patients.
Proinflammatory molecules introduced from the periphery may increase the brain
inflammatory pool via entry through systemic circulation and/or neural pathways [3].
Infections from Chlamydia pneumoniae, herpes simplex virus-1 (HSV-1), and
spirochetes have all been associated with AD [17]. Similarly, a recent study has shown
that common infectious agents such as influenza strains may initiate neuroinflammation
via olfactory neural networks [18]. Experimental amyloidosis has been induced
following injection of living, attenuated, or killed bacteria or bacterial components in
animals [19]. Bacterial inflammatory surface molecule lipopolysaccharide (LPS) is a
powerful inflammatory factor found in the outer membrane of Gram-negative bacteria
[19,20]. A study confirmed this by producing pathological changes common to AD
brains by chronic infusion of LPS in the fourth ventricle of a rat brain [21]. In vivo, LPS
has also been shown to increase the number of neurons that undergo apoptosis [22].
Lipopolysaccharide binds to receptor complexes at the surface of microglia and
stimulates production of pro-inflammatory cytokines, which in turn stimulate Aβ
production [7]. Bacterial remnants or dormant fastidious bacteria are able to persist in
infected organs as LPS and bacterial cell wall peptidoglycans are highly resistant to
degradation and may provide a persisting inflammatory stimulus [19]. Knowing that
inflammation plays a role in the induction and progression of AD, the next step is to look
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into the possibility of exogenous factors that may induce such inflammation. This
evidence provides indirect support for a role of C. pneumoniae in the development of
AD.
B. Chlamydia pneumoniae and Alzheimer’s Disease
The association between AD and C. pneumoniae infection was first investigated
by Balin et al. [23]. The study screened samples from AD patients using a polymerase
chain reaction (PCR) assay to determine the presence of C. pneumoniae. Analysis
showed that 17/19 AD patients were positive for the organism in areas of the brain with
typical AD-related neuropathology. Identical brain areas of a control group were
analyzed in a similar fashion, 18/19 patients were PCR-negative. Further investigation
using reverse transcription polymerase chain reaction assays confirmed that two C.
pneumoniae genes were present in AD brains but not control brains. Using several
techniques, C. pneumoniae was found to be present, viable, and transcriptionally active in
areas of neuropathology in the AD brain [23]. Further research by Little et al. has shown
that amyloid deposits resembling plaques found in AD brains were present in brains of
non-transgenic BALB/c mice following intranasal infection with C. pneumoniae. A
persistent infection was evident as density, size, and number of amyloid beta deposits
increased as the infection progressed. Of these deposits, a subset was found to exhibit
thioflavin-s labeling [17]. Presence of thioflavin-s indicates that the deposits are very
similar to fibril containing plaques formed with AD.
C. pneumoniae is an obligate intracellular bacterium that can be transmitted
through respiratory secretions, aerosols, and direct contact. It has been associated with
respiratory conditions such as bronchitis and sinusitis and causes about 5-15% of
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pneumonia cases. C. pneumoniae has also been associated with chronic diseases
including atherosclerosis, multiple sclerosis, meningoencephalomyeltis, and AD [24]. As
with all chlamydial species, C. pneumoniae undergoes a biphasic development cycle.
The first phase includes a metabolically inactive extracellular form, the elementary body,
which attaches to the eukaryotic host cell. The second phase is the reorganization into a
metabolically active form, the reticulate body. Reticulate bodies undergo several rounds
of cell division, after which 70-80% revert back to the elementary body form.
Propagation of the infection continues as newly synthesized elementary bodies exit the
host cell [25].
Persistent infection can occur as C. pneumoniae is able to alter its biologic state
based on availability of host cell nutrients and essential factors [25]. Studies have found
that astrocytes, microglia, and neurons can all serve as hosts for C. pneumoniae [15].
With chronic infection in such cells, the bacteria provide a continuous supply of toxins,
such as LPS. The aforementioned cytokines released due to the presence of LPS may
destabilize and permeabilize the blood brain barrier (BBB), offering a site of entry to the
CNS for foreign bodies or bacteria [7].
Further research has been conducted to confirm the findings that C. pneumoniae
is in fact present and viable in AD brain tissue. A study by Gérard et al. screened brain
tissue in 27 sporadic AD patients and found that 85% of the brains contained C.
pneumoniae and only 11% of control brains had the organism present. This study also
determined that C. pneumoniae-infected cells colocalize with both NSPs and NFTs, the
hallmark characteristics of AD. Real time polymerase chain reaction (RT-PCR) methods
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were used in this work to identify C. pneumoniae ribosomal RNA (rRNA) transcripts in
the brain tissue [26].
Despite the success of some research groups, not all studies have detected C.
pneumoniae in CNS tissue. These groups have independently failed to routinely detect
the organism using a variety of PCR and immunological techniques [27, 28, 29, 30, 31].
Variability in results demonstrates the need for a standardized detection method across all
research groups.
Work done by Boelen et al. examined the release of cytokines from C.
pneumoniae infected glial cells in order to determine if they were capable of causing
neuronal cell death [32]. Results from their study show that greater than 60% of
astrocytes stained positive for C. pneumoniae antigens while none of the control cells
showed such results. Significant levels of MCP-1, TNF-α, IL-10, and IL-6 were detected
in supernatant fluid from astrocytes. When using supernatant fluid from infected
microglial cells in transfer experiments with neuronal cells, necrosis of the cells was
significantly increased when compared to cells not presented with such fluid. The data
collected here suggests that once C. pneumoniae enters the brain, it may activate proinflammatory responses that can ultimately lead to neuronal cell death and ultimately
cause initiation or progression of AD [32].
C. Chlamydia pneumoniae Detection
i. Polymerase Chain Reaction (PCR)
Determining the presence or absence of C. pneumoniae in post-mortem AD brain
tissue will confirm or refute the possible association between the bacterium and the
disease. To this point, complement fixation assays (CF) have been used and accepted as
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a method for detecting C. pneumoniae. However, its lack of sensitivity and inability to
differentiate between infectious species has led to use of other methods such as
microimmunofluorescence (MIF). Although MIF has a higher level of specificity than
CF, it is still only able to demonstrate 63% maximum specificity [33]. Previous
laboratory work has shown that using a nested PCR method provided the most specificity
and sensitivity in C. pneumoniae detection [34].
Finding an assay that is both specific and sensitive is crucial as C. pneumoniae
may persist with only a small number of bacteria present. In turn, only small amounts of
bacterial DNA exist amongst a vast amount of host DNA. Polymerase chain reaction
(PCR) technology is on the forefront of methods that can be used to detect small amounts
of specific DNA sequences in a given sample. The development and consequent use of
PCR has allowed researchers to amplify genes in samples with increasing specificity and
selectivity. Khorana et al. first described the technique in the early 1970s, but the
development of the modern techniques now termed as PCR were established by Kary
Mullins in 1983 [35].
With PCR, DNA extracted from synthesized cell lines or tissue samples become the
target of amplification. More specifically, a sequence of interest within the DNA is
chosen for amplification and becomes the template for the reaction. In order to amplify
specific gene sequences, taq polymerase and synthetic primers are added to the DNA
sample and a series of three step cycles occur. The first step is a denaturing step that
separates the double-stranded DNA template by heating it to a temperature between 92°C
and 95°C. Once separated, the DNA cools to 55°C to 70°C for the annealing step in
which the primers bind to their complementary strands. The third and final step is an
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elongation step that occurs at 72ºC. Here, taq polymerase synthesizes a new DNA strand
in a 5` to 3` direction, between the forward and reverse primers, complimentary to the
DNA template. The product is a newly synthesized strand of DNA specific to the
primers chosen. The new DNA is used in subsequent cycles to produce millions of copies
of the target gene sequence.
ii. Nested PCR
To increase both sensitivity and specificity of the PCR products, nested PCR
(nPCR) can be utilized. Nested PCR uses two sets of primers, one outer and one inner, to
reduce the amount of amplified background genes and increase the specificity of the
target gene to be amplified. With nPCR, the product from the first round of amplification
using the outer primer is used as the template for a second round of amplification (Figure
1). In the second round of amplification, an inner primer amplifies a sequence within the
original amplified sequence [36]. This allows the PCR process to detect very small
amounts of target DNA within a large sample, such as C. pneumoniae in brain tissue.

Figure 1. Nested PCR Schematic
While nPCR uses multiple primers, the temperature cycling process is the same as
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non-nPCR. The cycle occurs between 30 and 40 times to synthesize up to 1 billion
copies of the original template DNA sequence. The entire reaction occurs in a thermal
cycling machine using very small amounts of reagents and DNA samples [36].
The use of nPCR techniques on infected brain tissue has potential to be a very
specific and sensitive method of C. pneumoniae detection. Through homogenization of
brain tissue, followed by DNA extraction, a sample can be produced that is viable for
nPCR. Using outer primers that are specific to multiple Chlamydia species (C.
pneumoniae and C. psittaci) and inner primers that are specific to only C. pneumoniae,
nPCR should be able to amplify DNA sequences to prove the presence or absence of C.
pneumoniae.
A study, validated by the CDC/LCDC, by Tong and Sillis utilized nPCR methods
in order to successfully detect both C. pneumoniae and C. psittaci. The outer primer
targeted the outer membrane protein gene (ompA) of both organisms and produced a 333
base pair (bp) product. The inner primer then amplified a region within the 333bp
product specific to C. pneumoniae only. These techniques were able to detect C.
pneumoniae in 10 of the 26 samples analyzed. Touchdown PCR was utilized in this
study by lowering the temperature by 1°C every two cycles from 65°C to 55°C in order
to increase primer specificity. Using elementary body counts, the first round of
amplification detected between 5 and 10 particles where as the second detected less than
one C. pneumoniae elementary body [32].
Other work considered valid by the CDC/LCDC was by Mahony et al.. This study
compared five published PCR assays to detect presence of C. pneumoniae. The five
assays were two conventional PCRs, one targeting a cloned PstI fragment and one
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targeting the 16S rRNA gene; two nPCRs, one targeting the 16S rRNA gene and one
targeting ompA; and a touchdown enzyme time release (TETR) PCR, targeting the 16S
rRNA gene. Results showed that all methods of PCR had similar sensitivities and could
detect a minimum of 0.005 infection forming units (IFU) of C. pneumoniae. The most
specific of the methods was the ompA nPCR and TETR PCR as they both detected 0.001
IFU. Both the ompA nPCR and TETR PCR also displayed the most reproducibility of all
the methods [34].
Mahony et al. continued to test PCR specificity by spiking U-937 mononuclear
cells with C. pneumoniae before adding them to whole blood. The five previously
mentioned assays were run in duplicate; all detected as few as 2.5 C. pneumoniaeinfected U-937 cells when added to 7 x 106 peripheral blood mononuclear cells (PMBCs)
from a clinical sample. Both the 16S rRNA standard assay and 16S rRNA nested assay
detected C. pneumoniae in one of two duplicate trials when samples were diluted to 3
infected U-937 cells. The 16S rRNA TETR assay detected C. pneumoniae at the same
dilution in both of the two duplicate trials. The ompA nested and cloned PstI did not
detect C. pneumoniae at this dilution, and none of the assays were able to detect the
organism at a dilution of 1.5 infected cells. The final portion of this study analyzed C.
pneumoniae DNA presence in PMBCs of patients with coronary artery disease (CAD).
The ompA nPCR detected C. pneumoniae DNA in 11/148 samples, and the 16S rRNA
nPCR detected C. pneumoniae DNA in 2/148 samples. The three other assays (Cloned
PstI, 16S rRNA standard, and 16S rRNA TETR) were unable to detect any samples
positive for C. pneumoniae DNA. The ompA assay was determined to be the most
specific for clinical trials. However, it was stated that more standardization and
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development of commercially available assays are needed to precisely identify C.
pneumoniae [34].
Gaydos et al. conducted a validated study similar to that of the Mahony group.
This study used a primer developed for the 16S rRNA of C. pneumoniae in regions that
differed from that of C. trachomatis and C. psittaci. Using these primers in PCR assays
with serial dilutions of DNA from C. pneumoniae elementary bodies, as few as 0.4 to 40
IFU of C. pneumoniae were detected. Throat specimens from humans with communityacquired pneumonia were then tested in the same manner. Of the 98 specimens, only 5
were positive for C. pneumoniae using the PCR assay, and none of the specimens yielded
C. pneumoniae cultures. Another part of this study examined specimens from the nostrils
and nasopharynx of two cynomolgus monkeys. Samples were taken prior to inoculation
and again at 1 week, 4 weeks, and 18 weeks post-infection. Of four specimens taken 4
weeks post-infection, 3 of them tested positive for C. pneumoniae by PCR, but none were
positive using culture methods. Additionally, frozen aliquots of samples that were
previously culture positive for C. pneumoniae were retested using PCR and culture
techniques. Seven of the eight tested positive using PCR while only one tested positive
using culture methods [34]. Results of this study display the greater sensitivity of PCR in
comparison to culture methods for detecting C. pneumoniae.
Due to the success of these studies in detecting C. pneumoniae, this work will also
attempt to detect the bacteria using similar methods. DNA will first be extracted from
mouse brain tissue that has been inoculated with C. pneumoniae and snap frozen in liquid
nitrogen upon collection and stored at -70°C. The DNA products will then be amplified
using a nested PCR that targets the ompA gene sequence of C. pneumoniae. The above
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work has displayed high specificity and sensitivity for the detection of C. pneumoniae.
a. Primers
As described by Boman et al., when selecting primers for use with PCR, several
requirements should be taken into account. Primer pairs should (i) amplify all strains of
the bacterium, (ii) amplify all strains with the same sensitivity, (iii) not amplify DNA
from other microbes, (iv) form stable duplexes with the template, (v) be 15 to 30
nucleotides long, (vi) have a high G+C content, (vii) not form 3’ end duplexes with
themselves, (viii) not contain homo-oligomers or short repeated sequences, (ix) be stable
at the 5' termini but somewhat unstable at the 3' ends, (x) be free of significant
complementarity at their 3' ends, (xi) have melting temperatures that are very close to
each other, and (xii) have a difference in melting temperatures with respect to the target
that does not exceed 20°C [35].
In the case of primer choice for C. pneumoniae detection, it is important to choose a
gene sequence that is highly conserved within the species, but should differ significantly
from other sequences in other Chlamydia species [35]. Using the gene sequence for
major outer membrane protein (ompA) is a C. pneumoniae specific target for the PCR
primers. When using a nPCR assay, both specificity and sensitivity increase because of
the multiple rounds of amplification being performed. With ompA nPCR, outer primers
first produce a 333bp amplicon from both C. pneumoniae and C. psittaci, but does not
amplify C. trachomatis. Next, using inner primers specific to C. pneumoniae, a 207bp
amplicon is produced as the final ompA nPCR product for detection [33]. As shown in
previous laboratory studies, ompA nPCR is a very specific and sensitive method for
detection of C. pneumoniae.
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Previous work in this lab has determined that PCR, using the ompA nested primer
set, was the most sensitive method for C. pneumoniae detection in comparison to
immunocytochemistry and immunofluorescence. Nested PCR was able to detect C.
pneumoniae DNA from samples containing 0.05 IFU. Furthermore, the nPCR method
detected C. pneumoniae DNA in 0.001 ratio samples of THP-1 cells that were diluted
1:100. In theory, this method should be able to detect a ratio of infected cells up to ten
infected cells in one million. This lab was also able to detect C. pneumoniae DNA from
mouse brains one month after being intranasally infected [34].
iii. Real-Time PCR (RT-PCR)
An alternative to traditional and nPCR assays is real-time PCR (RT-PCR). Realtime PCR uses primers and the same concept as traditional PCR, but allows for more
sensitivity and analytical capabilities. With RT-PCR, samples can be analyzed while the
reaction is in progress and details on amplification can be determined. Using traditional
PCR techniques, the amplification data is collected at the end point after several cycles
during the plateau phase of the reaction. Real-time PCR provides data during the more
specific exponential growth phase of the reaction. Post PCR processing such as agarose
gels are also eliminated with RT-PCR as data is collected and displayed in real time
throughout the reaction [36].
A study by Ménard et al. determined that Chlamydia psittaci can be detected in
human samples using RT-PCR techniques. Serial dilutions produced a linear regression
curve that had a slope very close to that of a corresponding maximum efficiency slope.
Additionally, the regression curve was linear from 10 6 to 1 bacterial genome per reaction
volume of 25μL [37].
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HYPOTHESIS AND GOALS
Hypothesis
Following infection with Chlamydia pneumoniae, olfactory bulb tissue will
consistently harbor genetic material specific to this pathogen. We also anticipate that the
infection will be present in frontal cortex brain tissue as that was the site of bacterial
injection.

Goals
a.) Confirm specificity and sensitivity for C. pneumoniae using PrimerDesign™
genesig 16s ribosomal RNA sequence kit on Chlamydia pneumoniae infected
cells grown in culture
b.) Use PrimerDesign™ genesig 16s ribosomal RNA sequence kit to detect the
presence or absence of C. pneumoniae in CNS tissue
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MATERIALS AND METHODS
I. Tissue Samples
Tissue samples used were frontal cortex and olfactory bulb tissues harvested from
the right hemisphere of BALB/c mice after direct intracranial injection with C.
pneumoniae AR-39. Tissue was infected with 1X103 IFU and was harvested at time
points of 3 and 14 days post infection, respectively.
II. Nucleic Acid Extraction
All nucleic acids were extracted using the same extraction buffer consisting of 25
mM Tris, 10 mM EDTA, 100μL NaCl, 0.5% SDS, 0.5% Triton-X, and 0.5% Tween 20.
Tissue samples were homogenized in 2mL of extraction buffer and the homogenate was
then placed in a 15mL plastic tube. One additional mL of extraction buffer was used to
rinse the homogenizer; this was then placed in the 15mL tube with the first 2mL of
extraction buffer. Proteinase K (6 μL, 20 mg/mL) was added to each sample and the tube
was allowed to incubate for at least 8 hours in a water bath at 35°C. After incubation,
1mL of phenol-chloroform was added to each sample and the tube was vortexed for 15
seconds. Samples were then placed in the same incubator as before at 65°C for 10
minutes. Simultaneously, 1mL of extraction buffer and 1mL of phenol-chloroform (per
sample) were heated to 65°C. The heated extraction buffer and phenol-chloroform were
added to the sample tube following rocking for 10 minutes. Samples were then placed in
a centrifuge (Thermo Scientific Sorvall ST 16R) and spun at 2000 rpm for 5 minutes at
21°C without braking. The aqueous phase was drawn off the top of the centrifuged
sample and the process was repeated twice more beginning at the step in which 1mL of
heated phenol-chloroform was added and vortexed for 15 seconds.
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After these steps were repeated twice, the aqueous phase of the final
centrifugation was placed in a 50mL centrifuge tube. The aqueous phase was then
precipitated with 2.5 volumes of ethanol and 0.1 volumes (after the ethanol is added) of
3M sodium acetate. The centrifuge tube was then placed in a -20°C freezer for at least 6
hours. Tubes were balanced with ethanol and centrifuged at 11,000 rpm (10,000g) using
a JA-21 rotor for 30 minutes at 4°C. Ethanol was decanted after centrifugation and the
tubes were allowed to dry upside down in a hood for 10 minutes. Biograde water
(500μL) was added to the dried tube to resuspend and soften the pellet. The suspended
DNA was then transferred to an eppendorf tube to be stored at 4°C.
III. Spectroscopy
Suspended DNA samples were analyzed using spectroscopy techniques to
determine content. Ten μL of sample was brought to 1000μL with water before being
transferred to a cuvette. Samples were analyzed at wavelengths of 260 nm, 280 nm, and
230 nm. Ratio values at each wavelength were calculated and recorded to determine
concentration (Table 1).
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Sample
OBR-001
OBL-001
OBR-002
OBL-002
OBR-005
OBL-005
OBR-006
OBL-006
OBR-007
OBL-007
OBR-008
OBL-008
OBL-014
OBR-017
OBL-017
OBR-018

Concentration
(ng/μL)
445
445
420
715
800
505
375
385
230
195
170
375
620
460
625
153

Dose
V.O.
V.O.
1X101
1X103
V.O.
V.O.
1X103
1X103
1X103
1X103
1X103
1X103
1X105
V.O.
V.O.
1X101

Harvest
Day PI
Day 3
Day 3
Day 3
Day 3
Day 3
Day 3
Day 3
Day 3
Day 3
Day 3
Day 3
Day 3
Day3
Day 7
Day 7
Day 7

Sample
OBL-018
OBR-019
OBR-052
OBR-053
OBR-054
OBR-055
OBL-055
OBR-056
FCR-005
FCR-006
FCR-007
FCR-008
FCR-053
FCR-054
FCR-055
FCR-056

Concentration
(ng/μL)
585
171
630
375
230
170
450
1209
1209
2415
1803
800
2415
1803
3120
--

Dose
1X101
1X101
1X101
V.O.
1X103
1X103
1X103
1X103
V.O.
1X103
1X103
1X103
1X103
V.O.
1X103
1X103

Harvest
Day PI
Day 7
Day 7
Day 14
Day 14
Day 14
Day 14
Day 14
Day 14
Day 3
Day 3
Day 3
Day 3
Day 14
Day 14
Day 14
Day 14

Table 1. Tissue samples for analysis. The concentration of DNA (ng/μL) from left and
right olfactory bulb (OBL and OBR) and right frontal cortex (FCR) tissue is given.
Treatment groups, amount of C. pneumoniae AR-39 injected (Dose) given in infectious
forming units (IFU) or vehicle only (V.O.), as well as days post injection (PI) are listed.
Total DNA concentration from sample FCR-056 was not determined.
From these isolated samples, OBR-005-008, FCR-005-008, OBR-053-056, and
FCR-053-056 were chosen as experimental samples for PCR testing. This group of
samples allowed for three experimental samples and one control sample at both day 3
post infection and day 14 post infection at an inoculation dose of 1X10 3 IFU.
IV. Nucleic Acid Amplification
Amplification of Chlamydia specific nucleic acids were performed using a real
time polymerase chain reaction (RT-PCR). The PrimerDesign™ genesig 16s ribosomal
RNA sequence RT-PCR advanced Chlamydia detection kit was used. The
manufacturer’s suggested protocol was included in the kit and used for our experiment.
All kit components were pulsed in a centrifuge and reconstituted using specified
amounts of RNAse/DNAse free water. After reconstitution, a Chlamydia detection mix
was prepared for all samples. Contents of the mix were 10μL 2X Precision™
MasterMix, 1μL Chlamydia Primer/Probe mix, 1μL Internal extraction control
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primer/probe mix, and 3μL RNAse/DNAse free water. All components were provided in
the kit, and volumes listed correspond to amount needed per reaction. A second detection
mix was also prepared as an endogenous control to confirm DNA integrity; this is done
through detection of the Actin Beta (ACTB) gene. The detection mix included 10μL 2X
Precision™ MasterMix, 1μL Endogenous ACTB Primer/Probe mix, and 4μL
RNAse/DNAse free water. In addition to primer mixes, the kit also included a
Chlamydia specific positive control, which was serially diluted to produce 6 dilutions in
accordance with the kit protocol. All components were provided in the kit and volumes
listed are amounts needed for one reaction.
The Chlamydia detection mix was prepared in a large volume that was enough for
all samples plus an additional 3-5 samples. Chlamydia detection mix (45μL) was
pipetted into empty centrifuge tubes that were previously labeled for specific tissue
samples. Once all tubes had 45μL of detection mix, 15μL of sample DNA corresponding
to the labeled tubes was added. The detection mix and DNA was briefly mixed by
flicking the tube before being pulsed in a centrifuge. After centrifugation, 20μL/reaction
was pipetted from the centrifuge tube into wells on a PCR plate that were previously
designated for each sample. This process was repeated for all samples until all were
loaded onto the PCR plate (Figure 2).
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Figure 2. RT-PCR Plate Preparation Schematic
This method was a slight deviation from the protocol provided with the kit. The
genesig protocol states that 15μL of detection mix should be added directly to the well
followed by 5μL of DNA sample. However, because the reactions were done in
triplicate, we made a stock of the detection mix and DNA mixture that could be aliquoted
into three individual wells; homogeneity of the samples was maximal in this way. All
PCR steps were performed in a PCR designated cabinet.
V. RT-PCR Data Collection
Using an Applied Biosystems 7000 Sequence Detection System, a plate
containing both samples and positive controls was first spun in a centrifuge for 5 minutes
at 1000rpm before being loaded into the machine. Wells were labeled using ABI Prism
7000 SDS Software to match the sample loaded and standards were defined prior to
running the reaction. Once the plate was loaded and wells were properly labeled, the
reaction parameters were set (Table 2).
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Step
Time
Temperature
1 Cycle
Enzyme Activation 10 mins
95°C
50 Cycles
Denaturation
10 sec
95°C
50 Cycles
Data Collection
60 sec
60°C
Table 2. Amplification conditions using PrimerDesign 2X Precision™ MasterMix

24

RESULTS
I. Nested PCR (nPCR)
The original protocol for this study used nested PCR as the basis for C.
pneumoniae detection. However, upon attempting to establish a positive control,
technical difficulties were encountered. Despite using both materials and methods that
had previously worked effectively in this lab, a positive control was not obtained. THP-1
cells infected with AR-39 did not produce a positive result when analyzed on an agarose
gel as they had during past studies in this laboratory (Figure 3).

Figure 3. OmpA Nested PCR Results A.) Previously run agarose gel after Chlamydia
specific PCR with well defined outer (333 bp) and inner (207 bp) DNA bands (within red
box) (Lanes 1-3: 48 hour PI 1.0, Lanes 4-6: 48 hour PI 0.1, Lanes 7-9: 48 hour PI 0.01,
Lane 10: Negative control (H2O), Lane 11: AR-39 Positive Control, Lane 12: DNA
Ladder)
B.) Recent agarose gel run after Chlamydia specific OmpA nested PCR, inner and outer
bands should have been present in lanes 3 and 5 (within red boxes) if proper
amplification of Chlamydia pneumoniae occurred. (Lane 1: DNA Ladder, Lane 2:
Empty, Lanes 3 and 5: 48 hour (MOI=0.75) AR-39 Infected THP-1 cells, Lane 4:
Empty, Lane 6: Empty, Lane 7: Uninfected THP-1 cells Lane 8: Empty) A total of 5μg
total DNA was loaded for all samples.
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To determine the cause for why a positive control could not be established,
several reaction components were replaced. Reagents were replaced; primers were
synthesized (Sigma Aldrich) and new PCR Beads (GE Healthcare illustra PuReTaq
Ready-To-Go™) were used as well, neither of which produced a positive result. DNA
purity and concentration, as well as salt concentration, was confirmed to be within
specified working range as previously established, but these conditions did not alter the
outcome. The source of error was not determined.
II. Real-Time PCR (RT-PCR)
Following the inability of nPCR to amplify C. pneumoniae specific sequences
from a positive control sample, a real-time technique was used to determine presence or
absence of the pathogen. To establish a positive control for the real-time reaction, 1X106
THP-1 cells were infected with C. pneumoniae AR-39 at an MOI of 0.75 for 48 hours.
DNA was extracted from the infected cells using the hot phenol method previously
described. Extracted DNA diluted to the following total content values of 2000ng,
400ng, 40ng, and 4ng were used as samples in an RT-PCR reaction to establish a positive
control for this technique. The reaction was able to detect the presence of Chlamydia in
every reaction (Table 3).
All the dilutions were positive for Chlamydia, including the lowest total DNA
content (4ng). A Chlamydia specific positive control included with the RT-PCR kit and
negative no template control yielded expected results. Samples were run in triplicate.
For experimental samples, if one of three triplicate reactions had a CT value of less than
40, the sample was considered positive for Chlamydia.

26

A. Detection of Chlamydia In Frontal Cortex and Olfactory Bulb Tissue At
Day 3 Post Infection
Samples from frontal cortex (FC) and olfactory bulb regions (OB) 005, 006, 007,
and 008 were tested along with a genesig series of positive control samples (P1-P6),
THP-1 infected cells, a no template control (NTC), and an endogenous actin control for
each experimental sample (ACTB) to ensure DNA quality. All experimental samples
were loaded at concentrations of 400ng/reaction and 800ng/reaction. THP-1 infected
cells used were diluted to 2000ng/reaction and 400ng/reaction. Samples P1-P5 were run
in dulicate while P6 and ACTB samples were run singly. The THP-1 dilutions, NTC, and
all experimental samples were run in triplicate. Cycle threshold (CT) values, quantity,
mean quantity, and standard deviation (SD) data was collected for all samples using ABI
Prism 7000 SDS Software (Table 4). If a sample did not cross the threshold at any point
during the reaction the CT values was given as undetermined (UD).
Threshold for all samples was set above the peak at which the NTC rose to during
the reaction. The positive control dilution series had mean CT values of 16.7 (±0.415)
for P1, 21.0 (±0.234) for P2, 24.6 (±0.117) for P3, 28.3 (±0.697) for P4, 32.2 (±0.112) for
P5, and 34.7 (±0.0) for P6. THP-1 infected cells had mean CT values of 18.2 (±0.299) at
2000ng and 20.9 (±0.064) at 400ng.
At 400ng/reaction, mean CT values for olfactory bulb samples were 45.8 (±3.666)
for OB-005R, undetermined for OB-006R, 40.3 (±2.562) for OB-007R, and 38.97 (2 of 3
reactions were undetermined) for OB-008R. At 800ng/reaction for the same samples,
mean CT values were 43.37 (2 of 3 reactions were undetermined) for OB-005R,
undetermined for OB-006R, 38.3 (± 1.289) OB-007R, and 49.7 (± 0.23) for OB-008R.
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Frontal cortex samples at 400ng/reaction had mean CT values of 42.3 (2 of 3
reactions were undetermined) for FC-005R, 49.94 (2 of 3 reactions were undetermined)
for FC-006R, 38.49 (2 of 3 reactions were undetermined) for FC-007R, and 44.54 (2 of 3
reactions were undetermined) for FC-008. At 800ng/reaction for the same samples, mean
CT values were 43.14 (2 of 3 reactions were undetermined) for FC-005R, undetermined
for FC-006R, 46.92 (2 of 3 reactions were undetermined) for FC-007R, and 45.07 (2 of 3
reactions were undetermined) for FC-008R.
The endogenous actin control had CT values of 33 for OB-005R at
400ng/reaction, undetermined for OB-005R at 800ng/reaction, 40.38 for OB-006R at
400ng/reaction, 39.58 for OB-007R at 400ng/reaction, 36.78 for OB-008R at
400ng/reaction, 40.94 for FC-005R at 400ng/reaction, 42.48 for FC-006R at
400ng/reaction, 42.61 for FC-007R at 400ng/reaction, and undetermined for FC-008R at
400ng/reaction.
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P1

16.7 ± 0.415

Mean
Quantity
1X106

OB-007R 400ng

40.3 ± 2.562

Mean
Quantity
9.22X10-1

P2

21.0 ± 0.234

1X105

OB-007R 800ng

38.3 ±1.289

2.32

P3

24.6 ± 0.117

1X104

FC-007R 400ng

38.49

P4

28.3 ± 0.697

1X103

FC-007R 800ng

46.92

P5

32.2 ± 0.112

1X102

OB-008R 400ng

38.97

1

OB-008R 800ng

49.7 ± 0.23

Sample Name

Mean CT

Mean CT

P6

34.7 ± 0.0

THP-1 (2000ng)

18.2 ± 0.299

344937.65

FC-008R 400ng

44.54

THP-1 (400ng)

20.9 ± 0.064

90771.49

FC-008R 800ng

45.07

NTC

UD

OB-005R 400ACTB
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OB-005R 400ng

45.8 ± 3.666

OB-005R 800ng

43.37

FC-005R 400ng

42.3

OB-005R 800ACTB
OB-006R 400ACTB
OB-007R 400ACTB

UD
40.38
39.58

FC-005R 800ng

43.14

OB-008R 400ACTB

36.78

OB-006R 400ng

UD

FC-005R 400ACTB

40.94

UD

FC-006R 400ACTB

42.48

FC-006R 400ng

49.94

FC-007R 400ACTB

42.61

FC-006R 800ng

UD

FC-008R 400ACTB

UD

OB-006R 800ng

1X10

Sample Name

4.39X10-2

1.58X10-3

Table 3. Mean CT value and copy number of Day 3-post infection olfactory bulb (OB)
and frontal cortex (FC) tissue. Mean CT ± standard deviation for controls P1-P6, THP-1
AR-39 infected cells, and experimental samples OB-005-008 and FC-005-008 are listed
as well as mean quantity of copy number.
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B. Detection Of Chlamydia In Frontal Cortex and Olfactory Bulb Tissue At Day 14
Post Infection
The target total content was 1500ng/reaction for samples isolated from day 14
post-infection animals. While testing day 14 samples, any samples from the day 3 post
infection group that had mean CT values greater than 40 or were undetermined were retested using 1500ng/reaction. THP-1 infected cells were diluted to 40, 4, 0.4, 0.04, and
0.004ng/reaction for comparison with experimental samples. All control and
experimental samples were run in triplicate, except OB-054R, which was run in
duplicate. Endogenous actin controls were run in singlet. Data was collected in the same
manner as the day 3 experimental samples using the ABI software; the threshold was
established as the peak of the NTC value.
The positive control dilution series had mean CT values of 17.2 (± 0.12) for P1,
23.3 (±0.29) for P3, 30.0 (±0.17) for P5, and 33.4 (±0.17) for P6. Mean CT values for
the infected THP-1 cells were 24.1 (±0.04) at 40ng/reaction, 27.4 (±0.32) at 4ng/reaction,
31.4 (±0.09) at 0.4ng/reaction, 33.7 (±1.2) at 0.04ng/reaction, and 37.5 (±1.5) at
0.004ng/reaction.
All olfactory bulb samples were tested at 1500ng/reaction, the mean CT values
were; 44.7 (±5.7) for OB-005R, 46.2 (±4.5) for OB-006, 39.1 (±0.25) for OB-008R,
45.56 (2 of 3 reactions were undetermined) for OB-053R, 42.2 (±1.2) for OB-054R, 38.3
(±2.7) for OB-055R, 41.6 (±4.4) for OB-056R.
Frontal cortex samples were tested at 1500ng/reaction, the mean CT values were;
44.8 (±3.7) for FC-005R, 38.1 (2 of 3 reactions were undetermined) for FC-006R, 43.6
(±5.3) for FC-007R, 42.5 (±3.5) for FC-008R, 43.5 (±2.6) for FC-053R, 40.84 (2 of 3

34

reactions were undetermined) for FC-054R, 44.7 (±4.5) for FC-055R, 42.8 (±4.8) for FC056R.
Endogenous actin control was tested using 1500ng/reaction for day 14 samples,
the CT value was 45 for FC-053R, undetermined for OB-054R, 49.73 for FC-054R,
36.42 for OB-055R, 44.57 for FC-055R, undetermined for OB-056R, 44 for FC-056R,
38.61 for FC-053R
Sample Name
P1
P3

Mean CT
17.2 ± 0.12
23.3 ± 0.29

Mean
Quantity
1X106

Sample Name

Mean CT

Mean
Quantity

OB-053R 1500ng

45.56

1X10

4

FC-053R 1500ng

43.5 ± 2.6

1.51X10-1

2

OB-054R 1500ng

42.2 ± 1.2

2.29X10-2

P5

30.0 ± 0.37

1X10

P6

33.4 ± 0.17

1X101

FC-054R 1500ng

40.84

THP-1 (40ng)

24.1 ± 0.04

6772.93

OB-055R 1500ng

38.3 ± 2.7

2.00X10-1

THP-1 (4ng)

27.4 ± 0.32

642.58

FC-055R 1500ng

44.7 ± 4.5

1.60X10-2

THP-1 (0.4ng)

31.4 ± 0.09

39.13

OB-056R 1500ng

41.6 ± 4.4

1.58X10-3

THP-1 (0.04ng)

35.7 ± 1.2

2.22

FC-056R 1500ng

42.8 ± 4.8

2.14X10-1

FC-008R 800ng

45.07

1.69X10-1

UD
40.38
39.58

THP-1 (0.004ng)
NTC

37.5 ± 1.5

3.83X10

-1

UD

OB-005R 1500ng

44.7 ± 5.7

2.93X10-2

FC-005R 1500ng

44.8 ± 3.7

2.07X10-2

OB-005R 800ACTB
OB-006R 400ACTB
OB-007R 400ACTB

OB-006R 1500ng

46.2 ± 4.5

5.32X10-3

OB-008R 400ACTB

36.78

FC-005R 400ACTB

40.94

FC-006R 1500ng

38.1

FC-007R 1500ng

43.6 ± 5.3

OB-008R 1500ng
FC-008R 1500ng

39.1 ± 0.25
42.5 ± 3.5

FC-006R 400ACTB

42.48

1.68X10

-1

FC-007R 400ACTB

42.61

8.93X10

-2

FC-008R 400ACTB

UD

5.68X10-2

Table 4. Mean CT value and copy number of day 3 and day 14-post infection olfactory
bulb (OB) and frontal cortex (FC) tissue. Mean CT ± standard deviation for controls P1,
P3, P5, and P6, THP-1 AR-39 infected cells, and experimental samples OB-005-008, FC005-008, OB-053-056, and FC-053-056 are listed as well as mean quantity of copy
number.
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DISCUSSION
The goals of this study were to confirm the sensitivity of the PrimerDesign™
genesig 16s ribosomal RNA sequence kit for Chlamydia in infected cells as well as CNS
tissue; and detect the presence or absence of C. pneumoniae in CNS tissue. C.
pneumoniae was detected in 48 hour infected THP-1 cells using the RT-PCR technique
specific for Chlamydia 16S RNA. Detection was capable on 2X106 C. pneumoniae
infected THP-1 cells (MOI=0.75) that had been diluted up to 1:500,000
(0.004ng/reaction). Thus, after dilution, the RT-PCR technique was able to detect about
3 infected cells in 2X106 cells. This ability of detection is consistent with a Mahony et
al. study that detected C. pneumoniae in as few as 3 infected cells using PCR techniques
[33]. Chlamydia was also detected using infected mouse brain tissue that was harvested at
day 3 and day 14-post infection. Both time points were inoculated with 1X103 IFU.
Upon analysis, it was decided that if one or more of the three reactions for each sample
had a CT value of less than 40, the sample was deemed positive (Table 5). This is
comparable to similar studies attempting to detect Chlamydia in samples. These studies
have performed up to 10 replicate reactions and accept the sample as positive if 2 of the
10 samples present are positive [Mahony]. A separate study also found that CT values
exceeded 30 when using clinical samples with low copy number [38].

40

Day

Sample

Frontal Cortex
Olfactory Bulb
[400] [800] [1500] [400] [800] [1500]
005
------------3
006
----+-------007
+---+--++ +++
008
----+--+--++053
----14
054
---055
--++056
--+
+-Table 5. Detection of C. pneumoniae in frontal cortex (FC) and olfactory bulb
(OB) tissue. Experimental samples were considered positive if one or more
triplicate reaction had a CT value less than 40, represented by (+). A CT that was
greater than 40 or undetermined is represented by (-), and an X indicates that the
samples was not tested at the specified DNA content level. Numbers in brackets
represent total DNA content in ng/reaction.
A possibility for inconsistencies across the triplicate reactions is the difficulty in
producing a completely homogeneous solution. Though measures were taken to increase
homogeneity, if there were, for example, 7 gene copies of interest in the
sample/MasterMix solution, one could pipette 3 to the first well, 4 to the second, and 0 to
the third, producing 2 positive and 1 negative results for a truly positive sample. This is
especially critical when dealing with samples containing low copy number. Other
research groups have utilized real-time PCR to consistently detect C. pneumoniae at copy
numbers as low as 5 [39] and 3 [40] per reaction. Samples were analyzed using auto
threshold settings before being manually set to just above the peak of the NTC samples.
A second source of inconsistency may lie in the amount of DNA used per reaction
compared to the total volume. Olfactory bulb and frontal cortex tissue were the only
experimental samples used, accounting for less than half of the CNS tissue exposed to the
direct infection with C. pneumoniae. Most samples were then resuspended in 500μL and
only 9μL can be used per reaction, thus only a small percentage, approximately 2%, of
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the resuspension is being tested in each reaction. The inability to test large fractions of
the total sample may have also impacted the inability of research groups to reproduce the
previously mentioned study by Balin et al. If only small segments of the brain are
harvested for DNA extraction, and only a small part of that extracted DNA is tested in
each reaction, a very small percentage of the total tissue is being tested. The inability to
definitively determine what area of CNS tissue has a substantial amount of C.
pneumoniae poses a great deal of ambiguity when testing small fractions of a total
sample.
I. Detection Of Chlamydia In Frontal Cortex and Olfactory Bulb Tissue At Day 3.
After testing day 3 samples at concentrations of 400ng/reaction and
800ng/reaction, interpretation of results suggested that using a higher DNA content per
sample may provide more accurate and consistent results. This interpretation was based
upon the observation that some samples were crossing the threshold late in the reaction or
only one of the three triplicate reactions was crossing the threshold. Using more
concentrated DNA would provide the reaction with more Chlamydia copy number per
sample volume if it were present. Boelen et al. used a range of 250 to 310 copies/μg to
consistently detect C. pneumoniae in olfactory bulb tissue using RT-PCR [41]. All
samples that did not have CT values in the range of 30-39 were to be re-analyzed along
with day 14 samples at a DNA content of 1500ng/reaction.
II. Detection Of Chlamydia In Frontal Cortex and Olfactory Bulb Tissue At Day 14.
THP-1 infected cells were diluted further for the day 14 samples in order to create
a standard curve that more closely parallel the CT range of experimental samples. Rather
than using THP-1 neat (2000ng/reaction) and 1:5 (400ng/reaction) dilutions as for day 3,
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the infected cells were diluted 1:50 (40ng/reaction), 1:500 (4ng/reaction), 1:5000
(0.4ng/reaction), 1:50,000 (0.04ng/reaction), and 1:500,000 (0.004ng/reaction) for day
14. This proved effective as CT values now ranged from 24 to 39 rather than just 19 to
21 as they did for the day 3 experiment.
Increasing the content to approximately 1500ng/reaction allowed for more
detection by increasing Chlamydia DNA to a detectable level if present. Trends in the
data show that by increasing the content, samples that were previously weakly positive or
even negative now show presence of Chlamydia.
When comparing samples that were tested using the 400ng/reaction,
800ng/reaction, and 1500ng/reaction, it can be seen that doubling the content from
400ng/reaction to 800ng/reaction does little to increase detection. Assigning undetected
samples a CT value of 50, the last cycle for the reaction, the average CT value at
400ng/reaction is 47.4 and at 800ng/reaction it is 47.6. Raising the content to
1500ng/reaction gives a mean CT value of 44.4. Additionally, 30 of the 48 samples were
undetected at both 400 and 800ng/reaction while at 1500ng/reaction 10 of the 44
reactions were undetected. This demonstrates that the most effective way to utilize this
technique is to test samples in lower replicate number using higher DNA content rather
than performing several replicate reactions at a lower DNA content. This may suggest
that about 1500ng of total DNA per reaction is approximately the limit of detection with
such low copy numbers.
Another interesting data observation comes from comparing location and days
post infection. All 3 of the experimental day 3 frontal cortex samples were positive for
Chlamydia while only 2 of the 3 day 3 experimental olfactory bulb samples produced
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positive results. Of the day 14 animals, 2 of the 3 experimental olfactory bulb samples
were positive for Chlamydia while only 1 of the 3 experimental frontal cortex samples
were positive. One would expect to encounter more Chlamydia in the frontal cortex at
day 3 than day 14, as it is the site of injection. It is also expected that more olfactory bulb
samples would be positive at day 14 than day 3 if the organism were to spread to other
areas of the brain away from the injection site.
Results from this study are comparable to similar independent studies performed
by other research groups. Using the PrimerDesign™ kit, C. pneumoniae was detectable
in infected THP-1 cells containing 0.106 copies per reaction. This detection limit is
comparable to other studies, which were able to detect less than 1 copy of C. pneumoniae
specific sequences per RT-PCR reaction as well [33,40,42, 43].
Another aspect of this study that is comparable to past studies is CT value. THP1 positive control samples for this study consistently had CT values ranging from 24 to
39. Copy number for these samples ranged from 7010 to 0.1 per reaction. Similar work
has detected low amounts of C. pneumoniae copy number at comparable CT values.
Apfalter et al. detected 3 copies of a C. pneumoniae specific sequence at a CT of 38.5;
this study detected 2 and 3 copies at CT values of 35.49 and 34.72, respectively [40].
Several other similar studies had comparable CT values ranging from 30-45 when
detecting less than 10 copies per reaction [38,39,42,44].
III. Future Directions
Although the technique used for this work was able to produce relevant data and
address goals set prior to the project, there are adjustments that could be made in order to
better utilize the technique. For experimental samples with potentially low pathogen
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copy number, using a minimum total DNA content of 2000ng/reaction would produce the
most favorable results. Using a higher DNA content will produce fewer undetermined
CT values and thus provide more data for interpretation.
Another adjustment that would benefit this study further would be to increase the
sample variety. While this study was only able to utilize samples at one inoculation
amount and two time points, it would be a beneficial change to add more time points with
multiple infection concentrations. Data from this alteration may help determine the
possibility of pathogen spreading over time when present in CNS tissue.

45

REFERENCES
[1] “What Is Alzheimer’s?” Alzheimer’s Association.
<http://www.alz.org/alzheimers_disease_what_is_alzheimers.asp>. 6/7/2011. Web. 3
October 2010.
[2] Buckley, Leonard L., and Tanja Schub. Quick Lesson About…Alzheimer’s Disease. Glendale:
CINAHL, 2004. Print.
[3] Kamer, Angela R., Craig, Ronald G., Dasanayake, Anada P., Brys, Miroslaw, GlodzikSobanska, Lidia, de Leon, Mony J. “Inflammation and Alzheimer’s disease: Possible
role of periodontal diseases.” Alzheimer’s & Dementia: The Journal of the Alzheimer’s
Association 4.4 (2008): 242-250. Print.
[4] Kantor, Daniel. “Alzheimer’s disease.”
http://www.nlm.nih.gov/medlineplus/ency/article/000760.htm. NIH. 4 October 2010.
Web. 16 October 2010.
[5] Alzheimer’s Disease Education & Referral (ADEAR) Center. Alzheimer’s Disease Genetics
Fact Sheet. Bethesda: NIH, 2008. Print.
[6] Alzheimer’s Association. “2011 Alzheimer’s disease facts and figures.” Alzheimer’s &
Dementia: The Journal of the Alzheimer’s Association 7.2 (2011): 208-244. Print.
[7] Urosevic, Nadezda, Martins, Ralph N. “Infection and Alzheimer’s Disease: The APOE ε4
Connection and Lipid Metabolism.” Journal of Alzheimer’s Disease. 13.4 (2008): 421435. Print.
[8] Relkin, Norman R. “Apolipoprotein E genotyping in Alzheimer’s disease.” The Lancet.
347.9008 (1996): 1091-1095. Print.
[9] Sando, Sigrid B., Melquist, Stacey, Cannon, Ashley, Hutton, Michael L., Sletvold, Olav,
Saltvedt, Ingvild, White, Linda R., Lydersen, Stian, Aasly, Jan O. “APOE ε4 lowers age
at onset and is a high risk factor for Alzheimer's disease; A case control study from
central Norway.” BMC Neurology. 8 (2008). Electronic.
[10] Gustaw-Rothenberg, Katarzyna. “ApoE genotype as risk factors for Alzheimer’s disease in
the population of Lublin region, Poland.” Journal of Pre-Clinical and Clinical Research.
2.2 (2008): 133-136. Print.
[11] Blacker, D., Haines, J.L., Rodes, L., Terwedow, H., Go, R.C.P. harrell, L.E., Perry, R.T.,
Bassett, S.S., Chase, G., Meyers, D., Albert, M.S., Tanzi, R. “ApoE-4 and age at onset of
Alzheimer’s disease: The NIMH Genetics Initiative.” Neurology. 48.1 (1997): 139-147.
Print.
[12] Querferth, Henry W., Laferia Frank M. “Mechanisms of Disease: Alzheimer’s Disease.”
The New England Journal of Medicine. 362.4 (2010): 329-244. Print.

46

[13] Conductier, Grégory, Blondeau, Nicolas, Guyon, Alice, Nahon, Jean-Louis, Rovère, Carole.
“The role of monocyte chemoattractant protein MCP1/CCL2 in neuroinflammatory
diseases.” Journal of Neuroimmunology. 224 (2010): 93-100. Print.
[14] Strohmeyer, Ron, Rogers, Joseph. “Molecular and cellular mediators of Alzheimer’s disease
inflammation.” Journal of Alzheimer’s Disease. 3.1 (2010): 131-157. Print.
[15] Honjo, Kie, van Reekum, Robert, Verhoeff, Nicolaas P.L.G. “Alzheimer’s disease and
infection: Do infectious agents contribute to progression of Alzheimer’s disease?”
Alzheimer’s & Dementia: The Journal of the Alzheimer’s Association. 5.4 (2009): 348360. Print.
[16] Grammas, Paula, Ovase, Roma. “Inflammatory factors are elevated in brain microvessels in
Alzheimer’s disease.” Neurobiology of Aging. 22.6 (2001): 837-842. Print.
[17] Little, C. Scott, Hammond, Christine J., MacIntyre, Angela, Balin, Brian J., Appelt, Denah
M. “Chlamydia pneumoniae induces Alzheimer-like amyloid plaques in brains of
BALB/c mice.” Neurobiology of Aging. 25.5 (2004): 419-429. Print.
[18] Majde, Jeannine A. “Neuroinflammation resulting from covert brain invasion by common
viruses–A potential role in local and global neurodegeneration.” Medical Hypotheses.
75.2 (2010) : 204-213. Print.
[19] Miklossy, Judith. “Chronic Inflammation and Amyloidogenesis in Alzheimer’s DiseaseRole of Spirochetes.” Journal of Alzheimer’s Disease. 13.4 (2008) 381-391. Print.
[20] Holmes, Clive, Cotterell, Darren. “Role of Infection in the Pathogenesis of Alzheimer’s
Disease.” CNS Drugs. 23.12 (2009) 993-1002. Print.
[21] Hauss-Wegrzyniak, Beatrice, Vraniak, Peter D., Wenk, Gary L. “LPS-induced
neuroinflammatory effects do not recover with time.” NeuroReport. 11.8 (2000): 17591763. Print.
[22] Cunningham, Colm, Wilcockson, David C., Campion, Suzanne, Lunnon, Katie, Perry, V.
Hugh. “Central and Systemic Endotoxin Challenges Exacerbate the Local Inflammatory
Response and Increase Neuronal Death during Chronic Neurodegeneration.” The Journal
of Neuroscience. 25.40 (2005): 9275-9284. Print.
[23] Balin, Brian J., Gérard, Hervé C., Arking, E. James, Appelt, Denah M., Branigan, Patrick J.,
Abrams, J. Todd, Whittum-Hudson, Judith A., Hudson, Alan P. “Identification and
localization of Chlamydia pneumoniae in the Alzheimer’s brain.” Medical Microbiology
and Immunology. 187.1 (1998) 23-42. Print.

47

[24] Guerra, L.G., Ho, H., Verghese, A., “New pathogens in pneumonia”, Medical Clinics of
North America 78 (1994): 967-985.
[25] Dreses-Werringloer, Ute, Bhuiyan, Mohammad, Zhao, Yinghao, Gérard, Hervé C.,
Whittum-Hudson, Judith A., Hudson, Alan P. “Initial characterization of Chlamydophila
(Chlamydia) pneumoniae cultured from the late-onset Alzheimer brain.” International
Journal of Medical Microbiology. 29.3 (2009): 187-201. Print.
[26] Gérard, Hervé C., Dreses-Werringloer, Ute, Wildt, Kristin S., Deka, Srilekha, Oszust,
Cynthia, Balin, Brian J., Frey II, William H., Bordayo, Elizabeth Z., Whittum-Hudson,
Judith A., Hudson, Alan P. “Chlamydophila (Chlamydia) pneumoniae in the Alzheimer’s
brain.” FEMS Immunology and Medical Microbiology. 48 (2006): 355-366. Print.
[27] Cagli, S., Oktar, N., Dalbasti, T., Erensoy, S., Özdamar N., Göksel S., Sayiner, A., Bilgiç,
A. “Failure to detect Chlamydia pneumoniae DNA in cerebral aneursymal sac tissue
with two different polymerase chain reaction methods.” Journal of Neurology,
Neurosurgery & Psychiatry. 74 (2003): 756-759. Print.
[28] Contini, Carlo, Seraceni, Silvia, Cultrera, Rosario, Castellazzi, Massimiliano, Granieri,
Enrico, and Fainardi, Enrico. “Chlamydophila pneumoniae Infection and Its Role in
Neurological Disorders.” Interdissciplinary Perspectives on Infectious Diseases. 2010
(2010): 1-18. Print.
[29] Wozniak, Matthew A., Cookson, Ann, Wilcock, Gordon K., Itzhaki, Ruth F. “Absence of
Chlamydia pneumoniae in brain of vascular dementia patients.” Neurobiology of Aging.
24 (2003): 761–765. Print.
[30] Gieffers, Jens, Reusche, Erich, Solbach, Werner, Maass, Matthias. “Failure to detect
Chlamydia pneumoniae in Brain Sections of Alzheimer’s Disease Patients.” Journal of
Clinical Microbiology. 38.2 (2000): 881-882. Print.
[31] Ring, Robert H., Lyons, Joseph M. “Failure to detect Chlamydia pneumoniae in the LateOnset Alzheimer’s Brain.” Journal of Clinical Microbiology. 38.7 (2000): 2591-2594.
Print.
[27] Boelen, E., Steinbusch, H.W.M., Pronk, I., Grauls, G., Rennert, P., Bailly, V., Bruggeman,
C.A., Stassen, F.R.M. “Inflammatory response following Chlamydia pneumoniae
infection of glial cells.” European Journal of Neuorscience. 25 (2007): 753-760. Print.
[28] Daugharty, H., Skelton, S.K., Messmer, T., “Chlamydia DNA Extraction for Use in PCR:
Stability and Sensitivity in Detection.” Journal of Clinical Laboratory Analysis. 12
(1998): 47-53. Print.
[29] Caruthers, Corey M. “Comparison of Detection Methods specific for Chlamydia
pneumoniae in Cell Cultures and in Experimental Mouse Tissue.” Masters Thesis. 2008.

48

[30] O’Leary, J.J., Engels, K., Dada, M.K. “The polymerase chain reaction in pathology.”
Journal of Clinical Pathology. 50 (1997): 805-810. Print.
[31] DeBiasi, Roberta L., Tyler, Kenneth L. “Polymerase Chain Reaction in the Diagnosis and
Management of Central Nervous System Infections.” Archives of Neurology. 56.10
(1999): 1215-1219. Print.
[32] Tong, C.Y., Sillis, M. “Detection of Chlamydia pneumoniae and Chlamydia psittaci in
sputum samples by PCR.” Journal of Clinical Pathology. 46 (1993): 313-317. Print.
[33] Mahony, J.B., Chong, S., Coombes, B.K., Smieja, M., Petrich, A. “Analytical Sensitivity,
Reproducibility of Results, and Clinical Performance of Five PCR Assays for Detecting
Chlamydia pneumoniae DNA in Peripheral Blood Mononuclear Cells.” Journal of
Clinical Microbiology. 38.7 (2000): 2622-2627. Print.
[34] Gaydos, Charlotte A., Quinn, Thomas C., Eiden, Joseph J. “Identification of Chlamydia
pneumoniae by DNA Amplification of the 16S rRNA Gene.” Journal of Clinical
Microbiology. 30.4 (1994): 796-800. Print.
[35] Boman, Jens, Gaydos, Charlotte A., Quinn, Thomas C. “ Molecular Diagnosis of Chlamydia
pneumoniae Infection.” Journal of Clinical Microbiology. 37.12 (1999): 3791-3799.
Print.
[36] “Real Time PCR vs Traditional PCR vs Digital PCR.” Applied Biosystems.
<http://www.appliedbiosystems.com/absite/us/en/home/applications-technologies/realtime-pcr/real-time-pcr-vs-traditional-pcr.html?ICID=EDI-Lrn2>. n.d. Web. 21 June 2011.
[37] Ménard, Armelle, Clerc, Maithé, Subtil, Agathe, Mégraud, Francis, Bébéar, Christiane, and
de Barbeyrac, Bertille. “Development of a real-time PCR for the detection of Chlamydia
psittaci.” Journal of Medical Microbiology. 55 (2006): 471-473. Print.
[38] Petyaev, Ivan M., Zigangirova, Nayilia A., Petyaev, Alexey M., Pashko, Ulia P., Didenko,
Lubov V., Morgunova, Elena U., Bashmakov, Yuriy K. “Isolation of Chlamydia
pneumoniae from serum samples of the patients with acute coronary syndrome.”
International Journal of Medical Sciences. 7.4 (2010): 181-190. Print.
[39] Leinard, Julia, Croxatto, Antony, Aeby, Sebastien, Aeby, Jaton, Katia, Posfay-Barbe, Klara,
Gervaix, Alain, Gilbert Greub. “Development of a New Chlamydiales-Specific RealTime PCR and Its Application to Respiratory Clinical Samples.” Journal of Clinical
Microbiology. 49.7 (2011): 2637-2642. Print.
[40] Apfalter, Petra, Barousch, Wolfgang, Nehr, Marion, Makristathis, Athanasios, Willinger,
Birgit, Rotter, Manfred, Herschl, Alexander M. “Comparison of a New Quantitative
ompA-Based Real-Time PCR TaqMan Assay for Detection of Chlamydia pneumoniae
DNA in Respiratory Specimens with Four Conventional PCR Assays.” Journal of
Clinical Microbiology. 41.2 (2003): 592-600. Print.

49

[41] Boelen, Ellen, Stassen, Frank R.M., van der Ven, André J.A.M., Lemmens, Marijke A.M.,
Steinbusch, Hellen P.J., Bruggeman, Cathrien A., Schmitz, Cristoph, Steinbusch, Harry
W.M. “Detection of amyloid bet aggregates in the brain of BALB/c mice after Chlamydia
pneumoniae infection.” Acta Neuropathologica. 114 (2007): 255-261. Print.
[42] Goldschmidt, P., Rostane, H., Sow, M., Goépogui, A., Batellier, L., Chaumeil, C.
“Detection by broad-range real-time PCR assay of Chlamydia species infecting human
and animals.” British Journal of Opthamology. 90 (2006): 1425-1429. Print.
[43] Hardick, Justin, Maldeis, Nancy, Theodore, Mellisa, Wood, Billie Jo, Yang, Samuel, Lin,
Shin, Quinn, Thomas, Gaydos, Charlotte. “Real-Time PCR for Chlamydia pneumoniae
Utilizing the Roche Lightcycler and a 16S rRNA Gene Target.” Journal of Molecular
Diagnostics. 6 (2004): 132-136. Print.
[44] Mygind, Tina, Birkelund, Svend, Falk, Erling, Christiansen, Gunna. “Evaluation of realtime quantitative PCR for identification and quantification of Chlamydia pneumoniae by
comparison with immunohistochemistry.” Journal of Microbiological Methods. 46
(2001): 241-251. Print.

